Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2025-12-25 @ 7:34 PM
Study NCT ID:
NCT05216432
Status:
RECRUITING
Last Update Posted:
2025-09-22
First Post:
2021-12-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Sponsor:
Relay Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-08
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-20
First Submit QC Date:
None
Study First Post Date:
2022-01-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-17
Last Update Post Date:
2025-09-22
Last Update Post Date Type:
ESTIMATED